For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Organogenesis Holdings Inc (NASDAQ: ORGO) was $5.08 for the day, down -1.93% from the previous closing price of $5.18. In other words, the price has decreased by -$1.93 from its previous closing price. On the day, 1.32 million shares were traded. ORGO stock price reached its highest trading level at $5.21 during the session, while it also had its lowest trading level at $5.035.
Ratios:
Our analysis of ORGO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.88 and its Current Ratio is at 3.32. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In the most recent recommendation for this company, Lake Street on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $5. On February 07, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $5. On June 15, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.Morgan Stanley initiated its Equal-Weight rating on June 15, 2023, with a $5 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 26 ’25 when NUSSDORF GLENN H sold 187,957 shares for $5.29 per share. The transaction valued at 994,293 led to the insider holds 2,765,591 shares of the business.
NUSSDORF GLENN H sold 100,000 shares of ORGO for $534,000 on Nov 24 ’25. The Director now owns 2,965,591 shares after completing the transaction at $5.34 per share. On Nov 25 ’25, another insider, NUSSDORF GLENN H, who serves as the Director of the company, sold 12,043 shares for $5.30 each. As a result, the insider received 63,828 and left with 2,953,548 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORGO now has a Market Capitalization of 644713664 and an Enterprise Value of 752629696. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.39 while its Price-to-Book (P/B) ratio in mrq is 2.53. Its current Enterprise Value per Revenue stands at 1.618 whereas that against EBITDA is 38.486.
Stock Price History:
The Beta on a monthly basis for ORGO is 1.47, which has changed by 0.30478585 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, ORGO has reached a high of $7.08, while it has fallen to a 52-week low of $2.61. The 50-Day Moving Average of the stock is 8.73%, while the 200-Day Moving Average is calculated to be 16.28%.
Shares Statistics:
ORGO traded an average of 1.51M shares per day over the past three months and 1474550 shares per day over the past ten days. A total of 126.91M shares are outstanding, with a floating share count of 58.83M. Insiders hold about 53.64% of the company’s shares, while institutions hold 54.13% stake in the company. Shares short for ORGO as of 1763078400 were 10880975 with a Short Ratio of 7.21, compared to 1760486400 on 11110375. Therefore, it implies a Short% of Shares Outstanding of 10880975 and a Short% of Float of 24.92.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 1.0 analysts currently analyzing and rating the stock of Organogenesis Holdings Inc (ORGO).The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.09 and low estimates of -$0.09.
Analysts are recommending an EPS of between $0.22 and $0.22 for the fiscal current year, implying an average EPS of $0.22. EPS for the following year is $0.17, with 1.0 analysts recommending between $0.17 and $0.17.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 2 analysts. It ranges from a high estimate of $173.3M to a low estimate of $172M. As of. The current estimate, Organogenesis Holdings Inc’s year-ago sales were $126.66MFor the next quarter, 2 analysts are estimating revenue of $99.7M. There is a high estimate of $103.7M for the next quarter, whereas the lowest estimate is $95.7M.
A total of 2 analysts have provided revenue estimates for ORGO’s current fiscal year. The highest revenue estimate was $511.9M, while the lowest revenue estimate was $510.2M, resulting in an average revenue estimate of $511.05M. In the same quarter a year ago, actual revenue was $482.04MBased on 2 analysts’ estimates, the company’s revenue will be $543.4M in the next fiscal year. The high estimate is $551.1M and the low estimate is $535.7M.
